Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)” (EBioMedicine (2020) 55, (S2352396420301547), (10.1016/j.ebiom.2020.102779))
- De Miguel, R.
- Rial-Crestelo, D.
- Dominguez-Dominguez, L.
- Montejano, R.
- Esteban-Cantos, A.
- Aranguren-Rivas, P.
- Stella-Ascariz, N.
- Bisbal, O.
- Bermejo-Plaza, L.
- Garcia-Alvarez, M.
- Alejos, B.
- Hernando, A.
- Santacreu-Guerrero, M.
- Cadiñanos, J.
- Mayoral, M.
- Castro, J.M.
- Moreno, V.
- Martin-Carbonero, L.
- Delgado, R.
- Rubio, R.
- Pulido, F.
- Arribas, J.R.
Zeitschrift:
eBioMedicine
ISSN: 2352-3964
Datum der Publikation: 2023
Ausgabe: 89
Art: Erratum